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1. Editorial/opinion piece
Many patients with advanced cancer will develop bone metas-
tases and associated complications, including severe pain and
debilitating skeletal-related events (SREs), which require radio-
therapy, surgery or changes to antineoplastic regimens [1–3].
Fortunately, there are effective treatments to prevent or delay
the onset of SREs. Several intravenous and oral bisphosphona-
tes have been used for over a decade. More recently, denosumab
(120 mg monthly, subcutaneous injection) has been added to the
ﬁeld of bone-targeted agents, having demonstrated superior
efﬁcacy over zoledronic acid (4 mg every 3–4 weeks, intravenous
injection), the previous standard of care [4]. However, a clinical
practice survey of patients with bone metastases suggests that
many patients have not been receiving optimal treatment [5].
This 2010 audit, conducted in France, Germany, Italy, Spain and
the United Kingdom, was divided into two sections. In the ﬁrst part,
physicians completed a brief questionnaire about all patients who
had bone metastases or who were being treated with bispho-
sphonates for cancer-related reasons. A detailed questionnaire was
then completed for the next 11 consecutive patients the physicians
saw who met the study criteria. Cases were weighted according to
the probability of prospective inclusion in the study (i.e. based on
patient consultation frequency and length of observation period).
Of the 17,193 patients included in the ﬁrst part of the audit, 35%
had prostate cancer, 21% of patients had breast cancer, 16% had
multiple myeloma and 11% had lung cancer. The remaining
patients had other solid tumors or non-Hodgkin's lymphoma.
Patient characteristics were largely consistent across the ﬁve
countries. Of concern, data from the brief questionnaires showed
that, of the patients with bone metastases (n¼14,871), only 53%
were receiving bisphosphonates (the only bone-targeted agents
available at the time of this study). One-ﬁfth had discontinued
treatment, 10% were expected to receive bisphosphonates in the
future and 17% were expected never to receive bisphosphonates.
Detailed questionnaires were completed for a further 9303
patients to establish the reasons behind the clinical practice
patterns. Reasons for bisphosphonate discontinuation were mainly
(in 56% of cases) listed as ‘end of treatment as planned’. Most
individuals who stopped treatment received bisphosphonates for
2 years or less (83%) and many (36%) received treatment for 1 year
or less. There was considerable variation across countries, from
14% of patients in Germany receiving bisphosphonates for 1 year
or less, to 64% of patients in the UK. Assuming patients are
tolerating bisphosphonates, the question remains why should
physicians plan a speciﬁc treatment duration? Notably, most major
guidelines do not recommend a restricted duration of therapy.
There are limited data on long-term administration of these
agents, but the information available suggests that the efﬁcacy
and safety proﬁles of bone-targeted agents are maintained over
time [6]. Therefore, in the absence of a toxicity or adherence issue,
there appears to be no obvious rationale to stop treatment.
Perhaps physicians are not fully aware of the risk-beneﬁt proﬁle of
bone-targeted agents? A poor risk-beneﬁt ratio and renal issueswere
key reasons for patients never receiving bisphosphonates, cited for
34% and 37% of individuals, respectively. Short life expectancy was
another major reason for not treating patients (38%), despite 72%
being at moderate-to-high risk of an SRE. Furthermore, over 60% of
these patients were considered by their treating physician to be
expected to live formore than 1 year. Considering that themean time
to an SRE is less than 2 months since diagnosis [7], with patients
experiencing events every 3–6 months thereafter [8], patients with
short life expectancies can still beneﬁt from treatment. The chief
objectives for treatment of patients with terminal cancer are pallia-
tion of symptoms andmaintenance of quality of life; these are just as
important when life expectancy is short. Bone-targeted agents can
help to achieve these aims by preventing worsening of pain and
avoiding the associated increased need for strong analgesics [9].
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Reassuringly, for the majority of patients in whom treatment with
bisphosphonates was delayed, the reason cited was ‘bone metastases
controlled by initial anti-tumour treatment’ (56%). The audit also
found, however, that a signiﬁcant proportion of patients had their
treatment delayed owing to safety concerns (31%), which included
existing renal impairment (61%), dental health issues (28%) and
avoidance of renal deterioration (20%). New bone-targeted agents that
are not contraindicated in renal impairment, such as denosumab, may
offer alternative options for patients whom physicians are reluctant to
treat with bisphosphonates owing to renal issues. While maintaining
dental health is important with both bisphosphonates and denosu-
mab, studies suggest that it may be possible to reduce the risk of
osteonecrosis of the jaw by carrying out preventive dental measures
prior to treatment with bone-targeted agents and by avoiding invasive
dental procedures while patients are on treatment [10–12].
The data also revealed notable differences in practice patterns
across the countries. In France, Italy, Spain and the UK, patients
were most likely to have multiple disseminated sites of metastases
at the time of initial bone metastasis detection; however, patients in
Germany were most likely to have a solitary bone metastasis. This
suggests that bone metastases were more likely to be detected at an
earlier stage in Germany than in other countries, meaning patients
potentially received bisphosphonate treatment for longer than
those in the other countries. Data from the audit on the circum-
stances surrounding bone metastasis detection supported this
theory, with routine screening for metastases being much more
common in Germany (38% of metastases were discovered this way)
than in the other four countries (6–24%). Germany may offer a good
example in this area as bone-targeted agents are beneﬁcial even
when initiated early in metastatic disease [1]. Thus, prompt
diagnosis may result in patients experiencing fewer SREs overall.
The results of this audit suggest that the clinical management of
bone metastases is at times suboptimal in these major European
countries. Data from a study of a US claims database conducted by
Hagiwara et al. [13] suggest that this issue is not conﬁned to Europe.
In their analysis, only 58.5% of patients with breast cancer received
intravenous bisphosphonates in the ﬁrst year after bone metastasis
detection, and this proportionwas even lower for thosewith prostate
or lung cancer. Although it is some years since these studies were
carried out,we believe that these data still have relevant implications
for clinical practice. The recent introduction of denosumabmay have
improvedaccess to treatment for patientswith renal impairment, but
other perceived barriers such as short life expectancy and short
planned treatment duration are likely to persist in the clinic.
Encouragingly, the Skeletal Care Academy steering committee
(composed of international experts in the ﬁeld of cancer-related bone
disease; oncologists, urologists, surgeons, nurses and patient advo-
cacy groups) has put together a Patient Charter, setting out the basic
requirements for standards of patient care in cancer-related bone
disease [14]. This charter emphasizes the need for a multidisciplinary
team who should understand the various management strategies
available for patients with bone metastases. Increasing physicians'
and nurses' awareness of different treatment strategies, together
with improved clinical practice guidelines on optimal treatment
duration and treatment of patients with short life expectancies,
may help to improve patient access to effective therapies. Further-
more, prompt detection of bone metastases, as seen in Germany, may
allow patients early access to bone-targeted agents, thereby delaying
or avoiding debilitating bone complications and pain.
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